AI Engines For more Details: Perplexity Kagi Labs You
Muscle Spasms: Chlorzoxazone is indicated for the relief of muscle spasms and stiffness associated with musculoskeletal conditions such as low back pain, neck pain, and muscle strains or sprains. It acts centrally on the nervous system to inhibit reflexes in the spinal cord, thereby reducing muscle tone and tension. Chlorzoxazone helps alleviate muscle spasms and discomfort, allowing for improved mobility and function.
Musculoskeletal Conditions: Chlorzoxazone may be prescribed for various musculoskeletal conditions characterized by muscle spasms, including acute and chronic conditions. It is often used as an adjunctive therapy in combination with rest, physical therapy, and other treatments to manage symptoms and promote recovery. Chlorzoxazone can provide symptomatic relief and facilitate rehabilitation in individuals with musculoskeletal injuries or conditions affecting the muscles and associated structures.
Acute Back Pain: Chlorzoxazone may be beneficial for individuals experiencing acute episodes of back pain due to muscle spasm or tension. It helps relax the muscles of the back and alleviate pain, allowing for improved mobility and function. Chlorzoxazone may be used short-term to manage acute episodes of back pain until symptoms resolve or as part of a comprehensive treatment plan.
Chronic Pain Syndromes: Chlorzoxazone may be used off-label in the management of chronic pain syndromes associated with muscle spasms, such as fibromyalgia or myofascial pain syndrome. While not specifically approved for these indications, chlorzoxazone's muscle relaxant properties may provide symptomatic relief and improve quality of life in individuals with chronic pain conditions characterized by muscle tension or spasm.
Side Effects: Common side effects of chlorzoxazone may include drowsiness, dizziness, lightheadedness, headache, nausea, and gastrointestinal upset. These side effects are usually mild and transient, and they may diminish with continued use or dose adjustment. Chlorzoxazone may cause drowsiness or impair cognitive and motor functions, so individuals should avoid driving or operating heavy machinery until they know how the medication affects them.
Contraindications: Chlorzoxazone is contraindicated in individuals with known hypersensitivity to the medication or any of its components, as well as those with a history of liver disease or impaired hepatic function. It should be used with caution in elderly patients and those with renal impairment. Chlorzoxazone may interact with other medications, including alcohol and central nervous system depressants, so it is important to inform the healthcare provider of all medications being taken.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Bacteroides | genus | Decreases | 👪 Source Study | |
| Bilophila | genus | Decreases | 👪 Source Study | High Level Cause Brain Fog(Cognitive impairment) |
| Coprococcus | genus | Decreases | 👪 Source Study | |
| Lachnospira | genus | Decreases | 👪 Source Study | |
| Thomasclavelia | genus | Decreases | 👪 Source Study | |
| Bacteroides fragilis | species | Decreases | 📓 Source Study | H02076 Bacteroides infection |
| Bacteroides xylanisolvens | species | Decreases | 📓 Source Study | |
| Thomasclavelia ramosa | species | Decreases | 📓 Source Study | |
| Lachnospira eligens | species | Decreases | 📓 Source Study | |
| Bilophila wadsworthia | species | Decreases | 📓 Source Study | |
| Coprococcus comes | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 0.3 | -0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.6 | 0.3 | 1 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alzheimer's disease | 1.2 | 1.7 | -0.42 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 1.2 | -1.2 | |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 1.2 | 0.3 | 3 |
| Atherosclerosis | 0.9 | 0.3 | 2 |
| Atrial fibrillation | 1.4 | 0.6 | 1.33 |
| Autism | 1.2 | 2.1 | -0.75 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0.3 | 0.3 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.9 | 0.9 | 0 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 0.3 | 1.1 | -2.67 |
| Chronic Kidney Disease | 0.3 | 0.9 | -2 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.6 | -1 |
| Chronic Urticaria (Hives) | 0.6 | -0.6 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 0.9 | 0.3 | 2 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 1.2 | -1.2 | |
| COVID-19 | 0.7 | 1.3 | -0.86 |
| Crohn's Disease | 1.4 | 1.8 | -0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.9 | 0.3 | 2 |
| Depression | 1.8 | 1.1 | 0.64 |
| Eczema | 0.6 | -0.6 | |
| Endometriosis | 0.6 | 0.6 | 0 |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.7 | 0.7 | |
| Fibromyalgia | 0.4 | 0.5 | -0.25 |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1.2 | 0.17 |
| gallstone disease (gsd) | 0.6 | 0.6 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Gout | 1.1 | 0.3 | 2.67 |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.6 | -1 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.9 | 0.9 | 0 |
| Heart Failure | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| hyperglycemia | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 1.8 | -2 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | 0 |
| Inflammatory Bowel Disease | 1.3 | 1.7 | -0.31 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.9 | 0.9 | 0 |
| ischemic stroke | 0.3 | 0.3 | 0 |
| Liver Cirrhosis | 1.4 | 0.9 | 0.56 |
| Long COVID | 1.2 | 1.5 | -0.25 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.5 | -0.5 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Metabolic Syndrome | 1.7 | 1.4 | 0.21 |
| Mood Disorders | 1.7 | 1.1 | 0.55 |
| Multiple Sclerosis | 0.3 | 1.5 | -4 |
| neuropathic pain | 0.6 | -0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 0.9 | 0.11 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.2 | 1.4 | -0.17 |
| obsessive-compulsive disorder | 1.2 | 0.6 | 1 |
| Osteoarthritis | 0.7 | 0.3 | 1.33 |
| Osteoporosis | 0.6 | 0.3 | 1 |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 1.4 | 1.9 | -0.36 |
| Polycystic ovary syndrome | 1.2 | 0.6 | 1 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 0.6 | 0.6 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 1.2 | 0 |
| Schizophrenia | 1.2 | 0.9 | 0.33 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.6 | -1 |
| Systemic Lupus Erythematosus | 1.4 | 0.3 | 3.67 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.4 | 0.6 | 1.33 |
| Type 2 Diabetes | 1.4 | 1.2 | 0.17 |
| Ulcerative colitis | 1.6 | 1.4 | 0.14 |
| Unhealthy Ageing | 1.4 | 0.3 | 3.67 |
| Vitiligo | 1.2 | 0.3 | 3 |
